Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A
Sponsor: Washington Institute for Coagulation
Summary
The investigators propose to study longitudinal joint and bone density changes in patients with severe Hemophilia A. Per current standard of care, most patients are on prophylactic FVIII replacement therapy intravenously several times weekly with a goal of keeping the trough \>1% FVIII. Recent phase 3 data suggest superior bleed protection with emicizumab prophylaxis every 1-2 weeks. It is the purpose of this study to longitudinally assess joint health and bone density over 3 years and to compare the effect of routine factor VIII prophylaxis with emicizumab prophylaxis.
Key Details
Gender
MALE
Age Range
16 Years - Any
Study Type
OBSERVATIONAL
Enrollment
40
Start Date
2019-04-04
Completion Date
2026-08
Last Updated
2023-09-05
Healthy Volunteers
No
Conditions
Interventions
assessment of joint health and bone density
We propose to study longitudinal joint and bone density changes in patients with severe Hemophilia A.
Locations (4)
Orthopedic Hemophilia Treatment Center
Los Angeles, California, United States
Hemophilia and Thrombosis Treatment Center, University of California, San Diego
San Diego, California, United States
The University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States
Washington Center for Bleeding Disorders at Washington Institute for Coagulation
Seattle, Washington, United States